China Summit Capital Joins $10M Series B Round In Impact Therapeutics

Chinese drug development start-up Impact Therapeutics has raised around US$10 million series B financing from new investors China Summit Capital, Guangzhou Yuexiu Industrial Investment Fund, Sungent Bioventure, Haibang Ventures and existing investor Lilly Asia Ventures, according to a company announcement. The company says it will use the proceeds to advance clinical studies and pipeline products. […]

Visit for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.

Read the original article: China Money Network